Congress directs NIH to accelerate research on a genetic disease affecting 500,000 Americans

What it does

This bill directs the National Institutes of Health (NIH) to expand research on polycystic kidney disease (PKD), a genetic disease affecting roughly 500,000 Americans that causes kidney failure and costs Medicare $3 billion annually. The bill requires NIH to intensify basic, translational, and clinical research; collaborate with academic and private partners; and establish a working group to develop a comprehensive research roadmap with recommendations due to Congress within 24 months.

Why we flagged it

The bill's sole operative mechanism is a directive to expand NIH research on a specific genetic disease and establish a coordinating working group. It is a straightforward public-health research authorization with no private carve-outs, tax provisions, or liability shields.

What the text implies

• The bill does not specify funding amounts or appropriations; research expansion depends on future congressional appropriations decisions, which may not materialize or may be inadequate.
• The working group's 24-month roadmap may recommend private-sector partnerships and incentives (e.g., tax credits, patent extensions, regulatory fast-track) that could shift some research costs or benefits to industry; the bill itself does not authorize these but may pave the way.
• Prioritization of PKD research may indirectly reduce resources available for other rare-disease research programs, though the bill does not explicitly cap total NIH funding.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill directs public research resources toward a serious genetic disease affecting 500,000 Americans, with clear potential to reduce kidney failure, dialysis dependence, and associated Medicare costs. No restrictions on citizen rights, remedies, or protections are imposed; the mechanism is purely additive research funding and coordination.

Who stands to gain

• academic research institutions (NIH grant recipients)
• pharmaceutical and biotech companies (potential private-sector collaborators in research and drug de

Named in the bill

National Institutes of Health (NIH), Institute (unspecified NIH institute, likely National Institute of Diabetes and Digestive and Kidney, Medicare End-Stage Renal Disease program, PKD patient advocacy organizations, Federal agencies, Academic institutions, Private sector stakeholders

Where it stands

7 cosponsors: 4 Republicans, 3 Democrats.

• Jun 4, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jun 4, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.